0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of Archives of Internal Medicine |

In This Issue of Archives of Internal Medicine FREE

Arch Intern Med. 2008;168(20):2182. doi:10.1001/archinte.168.20.2182.
Text Size: A A A
Published online

THROMBOLYTIC THERAPY AND MORTALITY IN PATIENTS WITH ACUTE PULMONARY EMBOLISM

Ibrahim et al conducted an analysis of 15 116 patient discharges with a primary diagnosis of pulmonary embolism from 186 acute care hospitals in Pennsylvania (January 2000–November 2002). In this statewide sample, thrombolytic therapy was used infrequently and was associated with a higher risk of both 30-day and in-hospital mortality in the large subgroup of patients with relatively low predicted probability of receiving thrombolysis, based on characteristics at presentation. Major bleeding was an uncommon complication of thrombolytic therapy.

See Article

ANTIDEPRESSANT USE, DEPRESSION, AND SURVIVAL OF PATIENTS WITH HEART FAILURE

To evaluate the association of depression and antidepressant therapy with long-term mortality, O’Connor et al studied 1006 patients 18 years or older with clinical heart failure (HF) and an ejection fraction of 35% or lower. They found that 30% of patients in the study were depressed (Beck Depression Inventory score ≥10), and 24.2% of these patients were taking antidepressants. During a mean (SD) follow-up of 972 (731) days, 42.7% of the study participants died. Overall, the use of antidepressants was associated with increased mortality (unadjusted hazard ratio [HR], 1.32; 95% confidence interval [CI], 1.03-1.69). However, the association between antidepressants and increased mortality no longer existed after controlling for depression and other confounders (HR, 1.24; 95% CI, 0.94-1.64). Nonetheless, depression remained associated with increased mortality after adjustment for baseline confounders and antidepressant use (HR, 1.33; 95% CI, 1.07-1.66). Thus, this study suggests that depression, but not antidepressant use, is associated with increased mortality in patients with HF.

See Article

INFLAMMATORY, LIPID, THROMBOTIC, AND GENETIC MARKERS OF CORONARY HEART DISEASE RISK IN THE WOMEN'S HEALTH INITIATIVE TRIALS OF HORMONE THERAPY

A nested case-control study found that 12 of 23 inflammatory, lipid, and thrombotic biomarkers (and 1 genetic marker) were associated with risk of coronary heart disease (CHD) in the Women's Health Initiative trials of postmenopausal hormone therapy (HT) (estrogen and estrogen plus progestin compared with placebo). The associations tended to be stronger during the first 2 years of the trials. Several biomarkers changed in response to HT. However, with the exception of baseline low-density lipoprotein cholesterol level (and possibly high-density lipoprotein cholesterol level), the biomarkers did not identify a subset of women who were at higher risk of CHD due to HT. Women with higher levels of low-density lipoprotein cholesterol were at significantly higher risk of CHD due to estrogen plus progestin therapy during the first 4 years of the trial. The findings suggest that it may be useful to measure the lipid profile prior to initiating HT.

See Article

SHORT SLEEP DURATION AS AN INDEPENDENT PREDICTOR OF CARDIOVASCULAR EVENTS IN JAPANESE PATIENTS WITH HYPERTENSION

Eguchi et al sought to examine if short sleep is associated with incident cardiovascular disease (CVD). Ambulatory blood pressure (BP) monitoring was performed at baseline in 1255 hypertensive subjects (mean [SD] age, 70.4 [9.9] years), who were followed up for 50 (23) months. The authors found that short duration of sleep (defined as <7.5 hours) was associated with an increased risk of CVD, and a synergistic interaction was observed between short sleep duration and the riser pattern (sleep BP > awake BP). Short duration of sleep is associated with incident CVD risk, and the combination of riser pattern and short duration of sleep is most strongly predictive of future CVD.

See Article

RAPID KIDNEY FUNCTION DECLINE AND MORTALITY RISK IN OLDER ADULTS

Impaired kidney function is associated with increased mortality risk in older adults. It remains unknown, however, whether longitudinal declines in kidney function are independently associated with increased cardiovascular and all-cause mortality in this population. In an analysis from the Cardiovascular Health Study, Rifkin et al calculated change in estimated glomerular filtration rate over 7 years of follow-up, using both cystatin C and creatinine-based measures of kidney function. Then they examined the relationship between rapid declines in kidney function (>mL/min/1.73 m2 per year) and mortality. Rapid decline by either measure of kidney function was associated with 50% to 70% increases in risk of cardiovascular and all-cause mortality in older adults, independent of baseline kidney function and other demographic variables. This result suggests that both the baseline level of kidney function and changes in kidney function over time should be considered risk factors for mortality in older adults.

Place holder to copy figure label and caption

Association of kidney function decline by cystatin C–based estimated glomerular filtration rate (eGFRcys) with all-cause mortality.

Graphic Jump Location

See Article

Figures

Place holder to copy figure label and caption

Association of kidney function decline by cystatin C–based estimated glomerular filtration rate (eGFRcys) with all-cause mortality.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.